The Pharmacy Times® Depression Resource Center is a comprehensive resource for clinical news and expert insights on treatments for the different forms of depression and its symptoms.
April 24th 2025
Because mothers are already at risk of depression postpartum, health care professionals must properly counsel mothers on hormonal contraceptives.
Exploring Therapeutic Advances for Bipolar Disorder With Mixed Features and Anxious Distress: An Update for Ph...
2.0 Credits / Neurology, Psychiatry
View More
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies
1.0 Credit / Law, Pain Management, Opioids
View More
Prescription Digital Therapeutics in Schizophrenia: A Managed Care Perspective on Advancements
2.0 Credits / Psychiatry
View More
Navigating Innovations: A Managed Care Perspective Addressing the Economic Burden of Schizophrenia
3.0 Credits / Psychiatry
View More
Managing Schizophrenia: Evidence-Based Care and Optimizing Value of New and Emerging Therapies
1.0 Credit / Psychiatry
View More
Research Finds Access to Recreational Marijuana Reduces Demand for Prescription Drugs
April 20th 2022When states legalize marijuana, the volume of prescriptions within the drug classes that align with the medical indications for pain, depression, anxiety, sleep, psychosis, and seizures significantly decline.
Read More
Experts Examine Ways to Reduce Global Burden of Depression
March 10th 2022The commission “Time for United Action on Depression,” authored by 25 experts from 11 countries, seeks to unify global efforts among governments, health care providers, researchers, people living with depression, and their families to improve care and prevention, fill knowledge gaps, and increase awareness.
Read More
AbbVie Seeks FDA Approval for Cariprazine for Adjunctive Treatment of Major Depressive Disorder
February 23rd 2022In a phase 3 study, there were clinically and statistically significant changes observed from baseline to week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score for patients treated with cariprazine at 1.5 mg/day versus the placebo.
Read More